AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05270460
Drug: PCS12852
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCS12852 oral tablet administered once daily
Trial: NCT05270460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator oral tablet administered once daily
Trial: NCT05849779
Drug: Intravenous sedation (current practice)
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In both arms, the management of sedation will be conducted in the broader picture of ICU patient care, as per current standard practice in participating ICUs, and following the current guidelines for Pain, Agitation, Delirium, Immobility, and Sleep Disruption (PADIS) published in 2018 by the Society of Critical Care Medicine.~Among many recommendations, this will include the monitoring and titration of both sedation and analgesia using validated scores such as the Richmond Agitation-Sedation Scale (RASS) for sedation. As a result of the current recommendations, the level, dose, and duration of sedation will vary among patients and will be decided by the treating clinicians. The choice of the analgesic drug(s) will be as per the treating clinicians.~Other aspects of critical care will adhere to standard care, including the use of the Checklist for Lung Injury Prevention (CLIP).
Trial: NCT06384248
Drug: LTC004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTC004,45μg/kg,IV,Day 1,Q3W;
Trial: NCT06313801
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2600 mg/m2 x intravenous infusion 24-hours (infusion of the samee of the total dose of fluorouracil for 48 hours) on day 1.
Trial: NCT06134830
Drug: RAI
RxNorm normalized name: PRAI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioactive iodine
Trial: NCT05918107
Drug: PM8002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05629468
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: antibiotic
Trial: NCT04847375
Drug: exogenous surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized Surfactant would be administered by face mask which has a nebulizer
Trial: NCT05629468
Drug: Probiotic Formula
RxNorm normalized name: Probiotic Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: probiotics
Trial: NCT06422429
Drug: Traditional deep-fried Youtiao
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45g 4 times a week for 4 months
Trial: NCT05320380
Drug: Hydrocortisone Sodium Succinate
RxNorm normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IT
Trial: NCT05320380
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT
Trial: NCT05320380
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IT
Trial: NCT05816070
Drug: IVIEW-1201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four times per day for day 1-2 and three times per day for day 3-7
Trial: NCT06576271
Drug: GSK4527363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK4527363 will be administered to participants.
Trial: NCT06576271
Drug: Placebo matching GSK4527363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching GSK4527363 will be administered to participants.
Trial: NCT05382182
Drug: androgen deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: outcome of hormonal treatment as androgen deprivation therapy on prostate cancer patient on survival and relapse
Trial: NCT04645823
Drug: Fentanyl Citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl citrate 20 µg in 2 ml of saline injected into csf
Trial: NCT05756972
Drug: PM8002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05756972
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04645823
Drug: Fentanyl Citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl citrate 100µg and lidocaine hydrochloride 80 mg in 10 ml volume
Trial: NCT05690698
Drug: Quatiapine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotic
Trial: NCT05438251
Drug: Fespixon Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Name: Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (approximately 2 mm in thickness)~5. Dosing schedule: Apply twice a day~6. Duration: up to 12 weeks
Trial: NCT04965870
Drug: Trifluridine/Tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluridine/ Tipiracil is an oral combination of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride.
Trial: NCT06213610
Drug: Prestarium® A tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prestarium® A is manufactured by Les Laboratoires Servier Industrie, France. Each tablet contains 10 mg of perindopril arginine.
Trial: NCT05948774
Drug: MT200605 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.
Trial: NCT05948774
Drug: MT200605 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 Placebo will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 Placebo for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.
Trial: NCT05608070
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline infusion at the rate of 83.3 ml/h.
Trial: NCT06495931
Drug: HR20033 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR20033 tablets, nine times
Trial: NCT06402968
Drug: Alternate IV Antihypertensive Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The alternate IV antihypertensive regimen would be the institutional standard management at designated non-clevidipine hospitals. It is expected that most of these sites will be using IV nicardipine, which if administered per FDA label is started at 5 mg/hour and increased by 2.5 mg/hour every 5-15 minutes to a maximum dose of 15mg/hour, until desired BP is reached. Once the goal is reached, then the dose may be reduced to 3 mg/hour.
Trial: NCT05823870
Drug: DW6014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: DW6014 Single oral administration of DW6014 after an overnight fast~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin after an overnight fast
Trial: NCT05491447
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment
Trial: NCT05178693
Drug: ASTX727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cedazuridine 100mg + 35mg decitabine
Trial: NCT00000937
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05226897
Drug: YYC405-T placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline cellulose, Subjects take the investigational products once a day for 24 weeks.
Trial: NCT05049343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution.
Trial: NCT05200728
Drug: SIM1910-09
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A-single ascending doses， SIM1910-09 will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose.~Part B-multiple ascending doses, SIM1910-09 will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.6mg/kg/h continuous infusion，which will be tested sequentially from low dose to high dose.
Trial: NCT05200728
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A-single ascending doses， placebo will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose.~Part B-multiple ascending doses, placebo will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.6mg/kg/h continuous infusion，which will be tested sequentially from low dose to high dose.
Trial: NCT04806633
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized in this arm will receive placebo.
Trial: NCT05098418
Drug: Poison
RxNorm normalized name: Plant poison
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard of care and propre antidotes will be provided for each poisoned patients in addition to gastric lavage and activated charcoal administration when it is applicable
Trial: NCT04787211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given by intravenous administration
Trial: NCT04992546
Drug: PRN473 (SAR444727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White to off-white gel suspension
Trial: NCT04992546
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White to off-white gel suspension
Trial: NCT06342648
Drug: Diclofenac Sodium injection
RxNorm normalized name: diclofenac sodium Injection
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injection of intramuscular diclofenac sodium
Trial: NCT06366334
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT02533219
Drug: 18 F-DOPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will undergo PET imaging with \[18F\]-DOPA. All PET imaging will be performed after administration of a single dose (0.08 - 0.16 mCurie/kg) of \[18F\]-DOPA. PET imaging can be performed on either Philips Ingenuity TF PET/MRI or PET/CT.
Trial: NCT02436044
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil, 1-st.400mg/m2, bolus injection, on day 1,every 3 weeks 2-nd.2400mg/m2, intraarterial infusion for 46 hours, on day 1-2,every 3 weeks
Trial: NCT02436044
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin, 200mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
Trial: NCT05493540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Group will receive Oral Placebo and Conservative therapy in the form of fluid restriction, PEEP, and/or diuretics~An Open-label option might be offered if there are concerns by attending physicians over the poor patient condition that might be attributed to persistent PDA:~1. Prolonged Ventilation or Escalating Ventilatory Setting~2. Prolonged Use Of Inotropes or Vasopressors or escalation of Doses~Rescue therapy in the form of a course of oral ibuprofen may be offered:~1. After 5 days of recruitment~2. Moderate/Severe PDA on Echocardiography~3. Prolonged ventilation or Increased ventilatory setting~4. Prolonged use of inotropes or vasopressors or escalating dose - Another form of treatment may be offered if the patient developed side effects from Ibuprofen
Trial: NCT05291572
Drug: medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brain stimulant
Trial: NCT05264558
Drug: Epclusa 400Mg-100Mg Tablet
RxNorm normalized name: Epclusa 400mg-100mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same day HCV test and treatment
Trial: NCT05651516
Drug: 18F-PI-2620 PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET/CT imaging will be used to evaluate the uptake of tau in the brain using the investigational radiotracer \[18F\]PI-2620. Each subject will have one \[18F\]PI-2620 positron emission tomography/computed tomography (PET/CT) scan performed.
Trial: NCT04639843
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin at 25 mg/ m2 by IV infusion on Day 1 of cycles 3-8.
Trial: NCT06332040
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: random assignment to gentamicin or placebo bladder instillation to prevent CAUTI (catheterized urinary track infection)
Trial: NCT05121831
Drug: DGX-001Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 1 of DGX-001
Trial: NCT05121831
Drug: DGX-001 Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 2 of DGX-001
Trial: NCT05121831
Drug: DGX-001 Dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 3 of DGX-001
Trial: NCT05121831
Drug: DGX-001 Dose 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 4 of DGX-001
Trial: NCT05307341
Drug: sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One dose of sufentanil 30 mcg sublingual pre-operatively upon entry to operating room and one dose of sufentanil 30 mcg sublingual in the PACU.
Trial: NCT05592041
Drug: Banaba Leaf Extract
RxNorm normalized name: banaba leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a herbal extract in the form of Bigel
Trial: NCT01600001
Drug: KWA-0711
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01600001
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05552807
Drug: SCT200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT04824222
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double cover, gastro-resistant, enteric release capsules with lactose (about 30-50 frozen capsules)
Trial: NCT04824222
Drug: SOC
RxNorm normalized name: Isocet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The standard COVID 19 pharmacological treatment
Trial: NCT06093945
Drug: SHR2554 tablet dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR2554 350mg taken on Day 1 and Day 10
Trial: NCT04939779
Drug: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT04939779
Drug: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT05974007
Drug: Neoadjuvant immunochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with operable stage I-III NSCLC who have previously undergone platinum drugs and immune checkpoint inhibitors(Anti PD-1) and then undergone radical surgery
Trial: NCT04749563
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of IGC AD1 oral Solution
Trial: NCT05940441
Drug: Capecitabine 500Mg Oral Tablet
RxNorm normalized name: Capecitabine 500mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg/m² body surface area twice daily for 1 year
Trial: NCT06216197
Drug: DEX group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The DEX Group, consisting of 29 patients, received 2.5 ml of hyperbaric bupivacaine mixed with dexmedetomidine (10 μg; 0.5 ml).
Trial: NCT05754801
Drug: Yunzhi Essence
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yunzhi Essence capsule
Trial: NCT05180708
Drug: QTORIN 3.9% rapamycin anhydrous gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QTORIN 3.9% rapamycin anhydrous gel
Trial: NCT05180708
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching vehicle (QTORIN anyhydrous gel)
Trial: NCT05157711
Drug: Anusol
RxNorm normalized name: ANUSOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily at night and in the morning and after each bowel movement for two weeks
Trial: NCT05157711
Drug: Relief [Name]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily at night and in the morning and after each bowel movement for two weeks
Trial: NCT05157711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily at night and in the morning and after each bowel movement for two weeks
Trial: NCT00914004
Drug: Desipramine HCl 50 mg Tablets Cord Laboratories
RxNorm normalized name: desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05182567
Drug: GLS-5310 (Group 1)
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLS-5310 DNA plasmid vaccine
Trial: NCT05182567
Drug: GLS-5310 (Group 2)
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLS-5310 DNA plasmid vaccine
Trial: NCT05182567
Drug: GLS-5310 (Group 3)
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLS-5310 DNA plasmid vaccine
Trial: NCT05182567
Drug: GLS-5310 (Group 4)
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLS-5310 DNA plasmid vaccine
Trial: NCT04797312
Drug: Opioid Free Anaesthesia protocol
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The OFA protocol begins with a systematic preoperative premedication with clonidine, continues with an adapted intraoperative management without opioid administration, but associating several molecules (clonidine, magnesium, lidocaine, ketamine) and ends with a continued administration of xylocaine up to 1 hour postoperatively in PACU. The use of an opioid in preoperative or intraoperative phases is considered as a deviation from the protocol.~To these different molecules, the use of hypnotic molecules left to the choice of the practitioner and a curare will be systematically associated.
Trial: NCT04682808
Drug: FCN-338
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCN-338 will be given orally in ascending doses starting at 50 mg QD until the maximum tolerated dose or recommended dose is reached.
Trial: NCT04879992
Drug: Tetracycline,Metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics for H. pylori eradication
Trial: NCT05265286
Drug: FRSW117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects of high dose group are being received four doses(50 IU/kg,once a week or every 7 days) of FRSW117.~Subjects of low dose group (40 IU/kg,once a week or every 7 days)are being received four doses of FRSW117.
Trial: NCT04842331
Drug: Standard of Care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive institutional SOC for the treatment.
Trial: NCT04790903
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive Cyclophosphamide at a dose of 750 mg/m\^2 by IV infusion or bolus on Day 1 of Cycles 1-6.
Trial: NCT04790903
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive Doxorubicin at a dose of 50 mg/m\^2 by IV infusion or bolus on Day 1 of Cycles 1-6.
Trial: NCT00000971
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05480241
Drug: Pancreatic Enzyme Replacement Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic Enzyme Replacement Therapy (PERT) 50000 Ph.U./meal + 25000 Ph.U./snack + Omeprazole 20mg once daily on fasting
Trial: NCT05480241
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Omeprazole 20mg once daily on fasting
Trial: NCT05265338
Drug: KC1036
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60mg QD
Trial: NCT04656288
Drug: BI 764198 - Formula B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 764198
Trial: NCT05117593
Drug: FBL-MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FBL-MTX is available as sterile liposomal dispersion for injection at nominal dose strength of 1 mg/mL of methotrexate free base. The dose of 0.1 mg was selected as starting dose in the present study. Three subsequent FBL-MTX dose levels are pre-planned: 0.33 mg, 1 mg and 2.5 mg.
Trial: NCT05117593
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will consist of sterile saline 0.9% NaCl solution.